Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Sarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Carcinoma, Renal Cell 3Wilms Tumor 2Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Kidney Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Astrocytoma 2

Interventions

Taxes 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Carboplatin 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1ixabepilone 1cediranib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1MK 2206 1GSK2141795 1Epothilones 1Cisplatin 1AZD 6244 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Endometrial Adenocarcinoma × ixabepilone × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡